Switzerland

Opna Bio Launches with $38 Million Series A Financing to Advance Novel Oncology Discovery Program and Diversified Pipeline of Clinical and Preclinical Programs

Gideon Bollag, PhD, Named CEO and Board Director.

Broad Drug Portfolio Targets Fragile-X Mental Retardation Protein (FMRP) in Cancer, Bromo and Extra Terminal (BET) Domain Proteins, Colony-stimulating Factor 1 Receptor (CSF1R), and Additional Cancer Drivers.

Seminal Research on FMRP’s Emerging Role in Cancer Published in Science.

Read more

About Opna Bio

Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company’s broad portfolio targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-X mental retardation protein (FMRP) and a diversified pipeline of validated oncology assets acquired from Plexxikon. The Opna team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market.

Stay connected!

image description
image description
image description
image description
image description